Clinical Trial Update: Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of entinostat in combination with aldesleukin for renal cell carcinoma, with results posted and the study listed as active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Entinostat (entinostat)
• Proleukin (aldesleukin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-02-24